Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04128072

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)

MOGAT: Open-Label, Phase II, Multi-Centre, Study of Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Stage IB-IIB Cutaneous T-Cell Lymphoma

Interventions Mogamulizumab Mogamulizumab (subsequent cycles post TSEB) Total Skin Electron Beam Therapy (TSEB)

Updated 13 times since 2019 Last updated: Apr 4, 2024 Started: Mar 7, 2023 Primary completion: Oct 31, 2026 Completion: Jan 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Stage IB-IIB Cutaneous T-Cell Lymphoma and is currently actively recruiting participants. European Organisation for Research and Treatment of Cancer - EORTC leads this study, which shows 13 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

13 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Dec 2023 — May 2024 [monthly]

Recruiting PHASE2
Aug 2023 — Dec 2023 [monthly]

Recruiting PHASE2

▶ Show 8 earlier versions

Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE2
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2022 — Mar 2023 [monthly]

Not Yet Recruiting PHASE2
Jan 2021 — Jul 2022 [monthly]

Not Yet Recruiting PHASE2
Oct 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2
Aug 2020 — Oct 2020 [monthly]

Not Yet Recruiting PHASE2
Nov 2019 — Aug 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Organisation for Research and Treatment of Cancer - EORTC

Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Barcelona, Spain , Birmingham, United Kingdom , Bordeaux, France , Brescia, Italy , Copenhagen, Denmark , Madrid, Spain , Manchester, United Kingdom , Mannheim, Germany , Minden, Germany and 2 more locations